Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

被引：0
作者：
Juliette Mathiaux
Valérie Le Morvan
Marina Pulido
Jacques Jougon
Hugues Bégueret
Jacques Robert
机构：
[1] Université de Bordeaux,Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 916
[2] Institut Bergonié,Hôpital du Haut
[3] Centre Hospitalier Universitaire de Bordeaux,Lévêque
[4] INSERM Centre d’Investigation Clinique (CIC)-EC7 et Unité de Recherche et d’Epidémiologie Cliniques,Institut Bergonié
[5] Institut Bergonié,undefined
来源：
Molecular Diagnosis & Therapy | 2011年 / 15卷
关键词：
Advanced NSCLC; Nucleotide Excision Repair; Adjuvant Setting; ERCC1 Expression; Nucleotide Excision Repair Gene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Cisplatin-based adjuvant treatment of non-small cell lung cancer (NSCLC) has become standard, thanks to the studies that have shown a significant survival advantage. The identification of patients who could benefit from this adjuvant treatment would allow ineffective and toxic administrations to be avoided. Immunohistochemical expression of the excision repair cross-complementation group (ERCC)-1 protein has been associated with response to platinum-based chemotherapy in patients with NSCLC, and some polymorphisms of the genes involved in DNA repair have been shown to be associated with survival in advanced NSCLC.
引用
收藏
页码：159 / 166
页数：7
相关论文
共 102 条
  • [1] Arriagada R(2004)Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 351-60
  • [2] Bergman B(2005)Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer N Engl J Med 352 2589-97
  • [3] Dunant A(2003)Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer J Natl Cancer Inst 95 1453-61
  • [4] Winton T(2006)Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Lancet Oncol 7 719-27
  • [5] Livingston R(2005)Cellular processing of platinum anticancer drugs Nat Rev Drug Discov 4 307-20
  • [6] Johnson D(1999)Molecular mechanism of nucleotide excision repair Genes Dev 13 768-85
  • [7] Scagliotti GV(2002)An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer J Natl Cancer Inst 94 1091-9
  • [8] Fossati R(2000)ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells Int J Cancer 89 453-7
  • [9] Torri V(2002)Cellular determinants of oxaliplatin sensitivity in colon cancer cells Eur J Cancer 39 112-9
  • [10] Douillard JY(2008)Excision repair cross-complementation group 1 in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature Lung Cancer 64 131-9
12345678910